Evidence map›Paper›PMID 29514064›Full record

ReviewCell metabolism2018

Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Luis Rajman, Karolina Chwalek, David A Sinclair

3 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 496 papers.

0numbers the graph read from it
0cells of the map it votes in
496citing papers in PubMed
43.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03973203 nacompletednot on this map

The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients

TypeinterventionalSponsorUniversity of HelsinkiRan2014 to 2018Enrolled15ConditionsMitochondrial MyopathiesArmsNiacin
NCT04538521 nacompletednot on this mapstarted 2019, after this paper: background citation

NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance

TypeinterventionalSponsorUniversity of HelsinkiRan2019 to 2020Enrolled3ConditionsMitochondrial MyopathiesArmsNiacin
NCT06991712 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Comparisons of Nicotinamide Adenine Dinucleotide (NAD) Precursors for Neuroenhancement in Glaucoma Patients

TypeinterventionalSponsorChristopher Kai Shun LeungRan2025 to 2026Enrolled138ConditionsGlaucomaArmsNicotinamide Riboside, Nicotinamide, Nicotinamide Mononucleotide, Nicotinic Acid, Placebo (Corn Starch)
3 · Its place in the literature

Who cites it

496 citing papers in PubMed, 828 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

436 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Luis RajmanPaul F. Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Karolina ChwalekPaul F. Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
David A SinclairPaul F. Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Laboratory for Ageing Research, Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: david_sinclair@hms.harvard.edu.
Harvard University · USUNSW Sydney · AU

Funding

Uncovering the Human SecretomeDP1AG058605 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2017 to 2021
$5.9M
Role of Sgs1 DNA helicase in telomere maintenanceR01AG019719 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SINCLAIR, DAVID A. · 2001 to 2022
$5.3M
SIRT1 as a regulator of health and lifespan of mammalsR37AG028730 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2012 to 2021
$4.1M
Elucidating mechanisms of SIRT1 activationR01DK100263 · NIDDK · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2016 to 2020
$2.5M
NIA NIH HHS DP1 AG058605NIA NIH HHS R01 AG019719NIA NIH HHS R37 AG028730NIDDK NIH HHS R01 DK100263
6 · The paper itself

Abstract

Nicotinamide adenine dinucleotide (NAD), the cell's hydrogen carrier for redox enzymes, is well known for its role in redox reactions. More recently, it has emerged as a signaling molecule. By modulating NAD

Indexed as

LongevityAnimalsEnergy MetabolismHumansNADSignal TransductionNADagingcancercardiovascular diseaseCD38chromatinepigeneticsinflammationnicotinamide mononucleotidenicotinamide ribosidePARP1sirtuinsSTAC

Identifiers

PMID29514064
PMCPMC6342515
OpenAlexW2791758888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.